FDA Approves Expanded Adjuvant Indications for Herceptin
May 23, 2008
US Food and Drug Administration's Division of Biologic Oncology Products has approved two new biologics license application (BLA) supplements expanding the approval of Genentech's Herceptin (trastuzumab) for the treatment of breast cancer.